Alkem Laboratories Ltd. ALKEM

Alkem Laboratories Ltd (BOM:539523) reports 11% revenue growth and strong India market outperformance, but faces net profit decline and US regulatory challenges.

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Generic Drug Market size & share revenue was valued at approximately USD 491.35 Billion in 2024 and is expected to reach USD 519.11 Billion in 2025 and is expected to reach around USD 926.54 Billion by 2034, at a CAGR of 6.55% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Alkem Laboratories Limited, T

Alkem Laboratories Ltd (BOM:539523) reports a 14.6% revenue growth and strategic advancements despite facing global challenges.

The chlorpheniramine maleate market is poised for growth due to rising allergic conditions, OTC antihistamine awareness, and pharmaceutical innovationDublin, May 01, 2026 (GLOBE NEWSWIRE) -- The "Chlorpheniramine Maleate Market Insights, Competitive Landscape, and Market Forecast - 2033" has been added to ResearchAndMarkets.com's offering. The global Chlorpheniramine Maleate Market is poised for significant growth, propelled by the rise in allergic conditions, heightened awareness of over-the-co

Indian pharma companies are releasing over 50 generic versions of Ozempic and Wegovy at eye-watering prices of $14 a month.

Esperion Therapeutics Inc (NASDAQ:ESPR) is among the best NASDAQ penny stocks to buy according to analysts. On February 17, Esperion Therapeutics Inc (NASDAQ:ESPR) struck a deal with Alkem Laboratories regarding the sale of rival generic drugs. Specifically, Esperion got Alkem to agree that it would not sell generic versions of Esperion’s drugs NEXLETOL and NEXLIZET […]